

Allen Andrew R  
 Form 4  
 November 21, 2011

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Allen Andrew R

2. Issuer Name and Ticker or Trading Symbol  
 Clovis Oncology, Inc. [CLVS]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

C/O CLOVIS ONCOLOGY, INC., 2525 28TH STREET, SUITE 100

3. Date of Earliest Transaction (Month/Day/Year)  
 11/21/2011

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
 See Remarks

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

BOULDER, CO 80301

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |   |
|---------------------------------|--------------------------------------|--|--------------------|---|---|--|-----------------------------------|---|
|                                 |                                      |  |                    | (A) or (D)  | Price   |  |                                   |   |
|                                 |                                      |  |                    | Code  | V   | Amount   |                                   |   |
| Common Stock                    | 11/21/2011                           |  | C                  | 3,567   | A   | 11   | 204,717                           | D |
| Common Stock                    | 11/21/2011                           |  | C                  | 3,567   | A   | 11   | 208,284                           | D |
| Common Stock                    | 11/21/2011                           |  | C                  | 7,721   | A   | 11   | 216,005                           | D |
| Common Stock                    | 11/21/2011                           |  | C                  | 3,153   | A   | 12   | 219,158                           | D |
| Common Stock                    | 11/21/2011                           |  | P                  | 3,846   | A   | \$ 13  | 223,004                           | D |

Edgar Filing: Allen Andrew R - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Series A-1 Convertible Preferred Stock     | (1)  | 11/21/2011                           |  | C                              | 10,345  | (1) (1)  | Common Stock  | 3,567                         |
| Series A-2 Convertible Preferred Stock     | (1)  | 11/21/2011                           |  | C                              | 10,345  | (1) (1)  | Common Stock  | 3,567                         |
| Series B Convertible Preferred Stock       | (1)  | 11/21/2011                           |  | C                              | 22,391  | (1) (1)  | Common Stock  | 7,721                         |
| Convertible Promissory Notes               | \$ 13  | 11/21/2011                           |  | C                              | \$ 40,000<br>(2)  | (2) (2)  | Common Stock  | 3,153<br>(2)                  |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |             |       |
|---|---------------|-----------|-------------|-------|
|   | Director      | 10% Owner | Officer     | Other |
| Allen Andrew R<br>C/O CLOVIS ONCOLOGY, INC.<br>2525 28TH STREET, SUITE 100<br>BOULDER, CO 80301 |               |           | See Remarks |       |

## Signatures

/s/ Andrew R.  
Allen

11/21/2011

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The reported securities were convertible at any time, in whole or in part, at the option of the reporting person, had no expiration date, and automatically converted into shares of Common Stock on November 21, 2011, the closing of the Issuer's initial public offering, on a 2.9 for 1 basis.

(2) The outstanding \$40,000 principal amount of these 5% convertible promissory notes due May 25, 2012 and all accrued and unpaid interest thereon from and after May 25, 2011 automatically converted into shares of Common Stock on November 21, 2011, the closing of the Issuer's initial public offering, at a conversion price of \$13.00, the per share price to the public of the Common Stock sold in the Issuer's initial public offering.

### Remarks:

Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.